🔎 Trials Near Me

Pradžia › B ląstelių limfoma › Utah

B ląstelių limfoma klinikiniai tyrimai Utah

8 tyrimai dėl B ląstelių limfoma ieško dalyvių vietose Utah.

Miestai Utah

Oficialus tyrimo tekstas (anglų kalba)

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

  • Intermountain Health, Canyons Region, LDS Hospital, Salt Lake City
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT06343311

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • Intermountain Healthcare, Salt Lake City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT07101328

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

  • Primary Children's Hospital, Salt Lake City
Renkami dalyviai1 fazė
Amžius nuo 0 iki 18 · Visoms lytims · Atnaujinta 2026-09-16 · NCT06173518

A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

  • Huntsman Cancer Institute, Salt Lake City
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-11 · NCT06634589

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • Huntsman Cancer Institute, Salt Lake City
  • Intermountain Healthcare, Salt Lake City
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-25 · NCT05826535

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Intermountain Healthcare, Salt Lake City
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-04 · NCT07188558

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

  • University of Utah, Salt Lake City
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-11-14 · NCT05643742

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Primary Children's Hospital, Salt Lake City
Renkami dalyviai1 fazė
Amžius nuo 1 iki 21 · Visoms lytims · Atnaujinta 2024-12-06 · NCT05476770

Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.